secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2025-10-03T23:59:59+00:00
Accession:  0001140361-25-037163
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma withdraws BLA for RP-L102 (Fanconi anemia gene therapy) as part of corporate prioritization
--------------------------------------------------------------------------------

- Voluntarily withdrew BLA for RP-L102 (mozafancogene autotemcel) from FDA on October 3, 2025.
- Withdrawal follows prior MAA withdrawal to European Medicines Agency in July 2025 and cessation of new internal investment in RP-L102 in July 2025.
- Decision based on business and strategic considerations; no safety or efficacy concerns noted.
- Company will explore external partnership opportunities to potentially advance RP-L102 in the future.
- Rocket is focusing resources on programs with clearest regulatory and commercial pathways.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125037163/0001140361-25-037163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125037163/ef20056613_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-037163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer